Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Biora Therapeutics (BIOR) Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
We thank Thomas Perry for taking the time to read and respond to our work. In the
OPTION-DM trial,1 we included pregabalin rather than gabapentin as pregabalin is a
twice-daily drug that made blinded dosing easier for the trial, has 3–4 times faster
absorption after oral administration, has dose-dependent predictable plasma concentration,
and requires a shorter titration period.2,3 Moreover, there was little rationale in
having two drugs with a similar mechanism of action. We disagree with the statement
“evidence for dose response from analgesics is tenuous” as some analgesics, such as
pregabalin, have dose-dependent efficacy.